Optimizing timing and cost-effective use of plasma biomarkers in Alzheimer’s disease

Optimizing timing and cost-effective use of plasma biomarkers in Alzheimer’s disease

Abstract Background and objectives Early and cost-effective identification of amyloid positivity is crucial for Alzheimer’s disease (AD) diagnosis. While amyloid PET is the gold standard, plasma biomarkers such as phosphorylated tau 217 (pTau217) provide a potential alternative. This study evaluates...

Full description

Saved in:
Bibliographic Details
Main Authors: Hsin-I Chang, Mi-Chia Ma, Kuo-Lun Huang, Chung-Gue Huang, Shu-Hua Huang, Chi-Wei Huang, Kun-Ju Lin, Chiung-Chih Chang
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer's disease
Amyloid positivity
Plasma biomarkers
Machine learning
pTau217
Early detection
Online Access:https://doi.org/10.1186/s13195-025-01851-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13195-025-01851-2

Similar Items